Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis
Authors:
Open Access
- 1 January 2022
- journal article
- review article
- Published by Elsevier in Value in Health
- Vol. 25 (1) , 133-146
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institute for Health Research
- Cancer Research UK
- University Hospitals Bristol NHS Foundation Trust
- University of Bristol
This publication has 83 references indexed in Scilit:
- Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost‐utility analysisBJU International, 2012
- Quality-of-Life Effects of Prostate-Specific Antigen ScreeningNew England Journal of Medicine, 2012
- Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriersBreast Cancer Research and Treatment, 2010
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screeningBritish Journal of Cancer, 2009
- Economic evaluation of prostate cancer screening with prostate‐specific antigenInternational Journal of Urology, 2008
- Good Practice Guidelines for Decision-Analytic Modelling in Health Technology AssessmentPharmacoEconomics, 2006
- Prostate cancer diagnosis: The impact on patients’ mental healthEuropean Journal of Cancer, 2006
- THE COST-EFFECTIVENESS OF COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE AND LUTEINIZING HORMONE RELEASING HORMONE AGONIST IN MEN WITH METASTATIC PROSTATE CANCERJournal of Urology, 2005
- Patient and Community Preferences for Outcomes in Prostate CancerMedical Care, 2003